Comments
Bharat Biotech International Limited and GCVC have entered into a contract manufacturing of the drug substance for Covaxin.
The GCVC comprises Gujarat Biotechnology Research Centre (GBRC), a Government of Gujarat undertaking, Hester Biosciences Limited and Omnibrx Biotechnologies Private Limited.
Also read: Bharat Bio makes a fresh bid to get Brazil’s nod for Covaxin
As per the MoU, Bharat Biotech shall provide the technology for the production of drug substance for Covaxin. GBRC will act as an advisor and mentor and will facilitate the technology transfer from Bharat Biotech. Hester shall provide the complete infrastructure at its Gujarat plant for the manufacturing of the Drug Substance and Omnibrx shall act as a technology support partner.
This entire process is facilitated by Department of Biotechnology.
If everything goes as per the schedule, the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing Covaxin.
Hester has estimated an outlay of ₹40 crore for this project. This proposed manufacturing activity at Hester would not disturb any manufacturing or marketing forecasts of Hester’s on-going business, for the financial year 2021-22, according to Rajiv Gandhi, CEO & Managing Director, Hester Biosciences Limited.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.